- Home
- PHAT vs NBTX Comparison
PHAT vs NBTX Comparison
Compare PHAT & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- NBTX
- Stock Information
- Founded
- PHAT 2018
- NBTX 2003
- Country
- PHAT United States
- NBTX France
- Employees
- PHAT N/A
- NBTX N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- PHAT Health Care
- NBTX Health Care
- Exchange
- PHAT Nasdaq
- NBTX Nasdaq
- Market Cap
- PHAT 769.0M
- NBTX 868.8M
- IPO Year
- PHAT 2019
- NBTX 2020
- Fundamental
- Price
- PHAT $11.70
- NBTX $29.60
- Analyst Decision
- PHAT Strong Buy
- NBTX Strong Buy
- Analyst Count
- PHAT 5
- NBTX 1
- Target Price
- PHAT $16.40
- NBTX $8.00
- AVG Volume (30 Days)
- PHAT 1.3M
- NBTX 139.7K
- Earning Date
- PHAT 11-06-2025
- NBTX 09-30-2025
- Dividend Yield
- PHAT N/A
- NBTX N/A
- EPS Growth
- PHAT N/A
- NBTX N/A
- EPS
- PHAT N/A
- NBTX N/A
- Revenue
- PHAT $114,039,000.00
- NBTX $11,930,711.00
- Revenue This Year
- PHAT $213.11
- NBTX N/A
- Revenue Next Year
- PHAT $91.84
- NBTX $74.67
- P/E Ratio
- PHAT N/A
- NBTX N/A
- Revenue Growth
- PHAT 1049.82
- NBTX N/A
- 52 Week Low
- PHAT $2.21
- NBTX $2.76
- 52 Week High
- PHAT $19.50
- NBTX $30.22
- Technical
- Relative Strength Index (RSI)
- PHAT 50.37
- NBTX 82.92
- Support Level
- PHAT $10.33
- NBTX $20.15
- Resistance Level
- PHAT $12.97
- NBTX $22.64
- Average True Range (ATR)
- PHAT 0.89
- NBTX 1.77
- MACD
- PHAT -0.11
- NBTX 1.14
- Stochastic Oscillator
- PHAT 45.41
- NBTX 97.82
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.